Walvax Biotechnology Co., Ltd. (300142.SZ)
CNY 10.0
(1.11%)
CNY 10.0
(1.11%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 4.11 Billion CNY | -19.75% |
| 2022 | 5.08 Billion CNY | 46.89% |
| 2021 | 3.46 Billion CNY | 17.82% |
| 2020 | 2.93 Billion CNY | 162.13% |
| 2019 | 1.12 Billion CNY | 27.55% |
| 2018 | 879.04 Million CNY | 31.54% |
| 2017 | 668.26 Million CNY | 13.07% |
| 2016 | 591 Million CNY | -41.25% |
| 2015 | 1 Billion CNY | 39.92% |
| 2014 | 719.02 Million CNY | 23.31% |
| 2013 | 583.09 Million CNY | 8.47% |
| 2012 | 537.55 Million CNY | 13.45% |
| 2011 | 473.81 Million CNY | 32.06% |
| 2010 | 358.79 Million CNY | 50.04% |
| 2009 | 239.12 Million CNY | 29.92% |
| 2008 | 184.06 Million CNY | 42.28% |
| 2007 | 129.36 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 828.42 Million CNY | 39.1% |
| 2024 Q3 | 707.99 Million CNY | -14.54% |
| 2024 Q1 | 595.58 Million CNY | -37.25% |
| 2023 Q2 | 1.33 Billion CNY | 60.14% |
| 2023 Q1 | 833.26 Million CNY | -39.63% |
| 2023 Q3 | 990.37 Million CNY | -25.78% |
| 2023 Q4 | 949.07 Million CNY | -4.17% |
| 2023 FY | 4.08 Billion CNY | -19.75% |
| 2022 FY | 5.08 Billion CNY | 46.89% |
| 2022 Q1 | 655.88 Million CNY | -50.82% |
| 2022 Q3 | 1.35 Billion CNY | -19.73% |
| 2022 Q2 | 1.69 Billion CNY | 157.99% |
| 2022 Q4 | 1.38 Billion CNY | 1.62% |
| 2021 Q4 | 1.33 Billion CNY | 71.09% |
| 2021 Q1 | 433.57 Million CNY | -68.4% |
| 2021 Q2 | 916.18 Million CNY | 111.31% |
| 2021 Q3 | 779.48 Million CNY | -14.92% |
| 2021 FY | 3.46 Billion CNY | 17.82% |
| 2020 Q1 | 112.19 Million CNY | -65.34% |
| 2020 Q2 | 461.26 Million CNY | 311.13% |
| 2020 FY | 2.93 Billion CNY | 162.13% |
| 2020 Q3 | 993.3 Million CNY | 115.35% |
| 2020 Q4 | 1.37 Billion CNY | 38.15% |
| 2019 Q2 | 324.29 Million CNY | 84.02% |
| 2019 FY | 1.12 Billion CNY | 27.55% |
| 2019 Q1 | 176.22 Million CNY | -42.35% |
| 2019 Q3 | 296.96 Million CNY | -8.43% |
| 2019 Q4 | 323.73 Million CNY | 9.02% |
| 2018 Q1 | 117.7 Million CNY | -49.53% |
| 2018 FY | 879.04 Million CNY | 31.54% |
| 2018 Q3 | 198.79 Million CNY | -22.61% |
| 2018 Q4 | 305.67 Million CNY | 53.76% |
| 2018 Q2 | 256.86 Million CNY | 118.23% |
| 2017 Q3 | 178.33 Million CNY | 4.58% |
| 2017 FY | 668.26 Million CNY | 13.07% |
| 2017 Q1 | 86.17 Million CNY | -55.44% |
| 2017 Q2 | 170.52 Million CNY | 97.89% |
| 2017 Q4 | 233.23 Million CNY | 30.79% |
| 2016 Q3 | 104.62 Million CNY | 27.56% |
| 2016 FY | 591 Million CNY | -41.25% |
| 2016 Q1 | 210.97 Million CNY | -28.43% |
| 2016 Q4 | 193.38 Million CNY | 84.84% |
| 2016 Q2 | 82.01 Million CNY | -61.12% |
| 2015 Q2 | 241.48 Million CNY | 40.18% |
| 2015 FY | 1 Billion CNY | 39.92% |
| 2015 Q4 | 294.77 Million CNY | -0.92% |
| 2015 Q3 | 297.5 Million CNY | 23.2% |
| 2015 Q1 | 172.26 Million CNY | 30.3% |
| 2014 Q1 | 186.75 Million CNY | -18.48% |
| 2014 Q2 | 214.95 Million CNY | 15.1% |
| 2014 Q3 | 185.1 Million CNY | -13.89% |
| 2014 Q4 | 132.2 Million CNY | -28.58% |
| 2014 FY | 719.02 Million CNY | 23.31% |
| 2013 Q1 | 94 Million CNY | -49.37% |
| 2013 Q2 | 141.19 Million CNY | 50.2% |
| 2013 Q3 | 118.82 Million CNY | -15.84% |
| 2013 Q4 | 229.07 Million CNY | 92.78% |
| 2013 FY | 583.09 Million CNY | 8.47% |
| 2012 Q2 | 173.1 Million CNY | 211.83% |
| 2012 Q1 | 55.51 Million CNY | -68.88% |
| 2012 FY | 537.55 Million CNY | 13.45% |
| 2012 Q4 | 185.68 Million CNY | 50.64% |
| 2012 Q3 | 123.26 Million CNY | -28.79% |
| 2011 Q3 | 114.84 Million CNY | -13.13% |
| 2011 Q4 | 178.37 Million CNY | 55.32% |
| 2011 Q1 | 48.4 Million CNY | -64.19% |
| 2011 FY | 473.81 Million CNY | 32.06% |
| 2011 Q2 | 132.19 Million CNY | 173.1% |
| 2010 Q2 | 91.74 Million CNY | 163.15% |
| 2010 FY | 358.79 Million CNY | 50.04% |
| 2010 Q4 | 135.17 Million CNY | 39.35% |
| 2010 Q3 | 97 Million CNY | 5.73% |
| 2010 Q1 | 34.86 Million CNY | 0.0% |
| 2009 FY | 239.12 Million CNY | 29.92% |
| 2008 FY | 184.06 Million CNY | 42.28% |
| 2007 FY | 129.36 Million CNY | 0.0% |